Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

jor programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

* the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

* the safety and efficacy of the Company's products or product candidates;

* the Company's assessment of its clinical trials;

* the commencement and completion of clinical trials;

* the Company's ability to develop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license and

collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... YORK, March 31, 2011 Intercept Pharmaceuticals, Inc., today ... double-blind  Phase II clinical trial of obeticholic acid (OCA) ... (PBC).  The study evaluated the effects of 10 mg ... patients with elevated alkaline phosphatase (AP).  AP is a ...
... Services Corp., a leading provider of pharmaceutical product ... of Dean Shirazi, Ph.D., to Vice President, Analytical ... 4, 2011. (Logo:   https://photos.prnewswire.com/prnh/20110330/CG74146LOGO ) ... in June 1992 as a Senior Scientist, has ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 3AAIPharma Services Announces Promotion of Dean Shirazi 2
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
(Date:12/17/2014)... 2014 Now in its second year, ... of the best in senior living and home care ... to communities and agencies that have received outstanding online ... the nearly 100,000 providers currently listed on SeniorAdvisor.com, only ... SeniorAdvisor.com Best of 2015 Awards are located all over ...
(Date:12/17/2014)... 2014 (HealthDay News) -- As gas prices rose in ... new study suggests. In times of gas increases, ... riders are inexperienced, the researchers explained. They examined ... has the highest number of motorcycle registrations in the ... deaths. The analysis revealed a strong association between ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Expectant parents ... Food and Drug Administration recommends. Use of ultrasound ... videos is not entirely risk-free, the agency warns. ... any harm due to ultrasound imaging and heartbeat monitors, ... providers is important," Shahram Vaezy, an FDA biomedical engineer, ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... of $5.2 Million Lifted, SALT LAKE CITY, ... ), the only U.S.-based publicly traded manufacturer of,digital ... subsidiary,successfully negotiated an amendment with Commerzbank AG, a ... acquisition of the German subsidiary. The,amendment resulted in ...
... but researchers from Tel Aviv University have found good reasons ... Dr. Liran Levin, a dentist from the Department of Oral ... found that about 15 to 20 percent of teens with ... and gum disease. Resulting tooth fractures as well as periodontal ...
... of Physicians (ACP) today commended the Medicare Payment Advisory ... primary care in a well-functioning health-care delivery system in ... MedPAC in a letter to Glen D. Hackbarth, chairman ... the U.S. Congress on issues affecting the Medicare program. ...
... boys , , FRIDAY, June 20 (HealthDay News) -- Summer ... is gearing up to warn players and their fans ... Baseball, the Major League Baseball Players Association and the ... 10th annual Play Sun Smart campaign on that day, ...
... 20 A team of medical,professionals from the ... services in Germany impressive. The NRH team has ... the US Army,s Europe Regional,Medical Command (ERMC) in ... and capability of our military health care system ...
... . , Finger ring dosemeters are used at diverse ... order to check whether the effective dose limt values are ... been subjected to an annual quality control by the PTB ... in Germany have passed these controls. , In Germany, ...
Cached Medicine News:Health News:Sonic Innovations Announces Loan Amendment With German Bank 2Health News:Sonic Innovations Announces Loan Amendment With German Bank 3Health News:Warning for teens: Teeth and jewelry don't mix 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 3Health News:Pro Baseball Helps Keep Skin Cancer From Scoring 2Health News:Pro Baseball Helps Keep Skin Cancer From Scoring 3Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 2Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 3Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 4Health News:PTB testing method for finger ring dosemeters has proven its effectiveness 2
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
S.O.C. Medium...
... rHead Radial Implant System provides todays ... to radial head replacement. Modular ... patient anatomy while minimizing ligamentous and ... designed alignment guide assists in both ...
Medicine Products: